Intuitive Surgical/$ISRG
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Intuitive Surgical
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 9,500 da Vinci systems in hospitals worldwide, with more than 5,500 installations in the US and a growing number in emerging markets.
Ticker
$ISRG
Sector
Primary listing
Employees
15,638
Headquarters
Website
ISRG Metrics
BasicAdvanced
$157B
61.11
$7.17
1.65
-
Price and volume
Market cap
$157B
Beta
1.65
52-week high
$616.00
52-week low
$425.00
Average daily volume
2.4M
Financial strength
Current ratio
7.61
Quick ratio
6.593
Profitability
EBITDA (TTM)
3,185.7
Gross margin (TTM)
66.61%
Net profit margin (TTM)
28.51%
Operating margin (TTM)
29.03%
Effective tax rate (TTM)
11.90%
Revenue per employee (TTM)
$580,000
Management effectiveness
Return on assets (TTM)
9.01%
Return on equity (TTM)
16.04%
Valuation
Price to earnings (TTM)
61.114
Price to revenue (TTM)
17.108
Price to book
8.75
Price to tangible book (TTM)
8.98
Price to free cash flow (TTM)
78.45
Free cash flow yield (TTM)
1.27%
Free cash flow per share (TTM)
5.585
Growth
Revenue change (TTM)
20.77%
Earnings per share change (TTM)
23.20%
3-year revenue growth (CAGR)
15.32%
10-year revenue growth (CAGR)
15.06%
3-year earnings per share growth (CAGR)
22.37%
10-year earnings per share growth (CAGR)
17.00%
What the Analysts think about ISRG
Analyst ratings (Buy, Hold, Sell) for Intuitive Surgical stock.
Bulls say / Bears say
In Q2 2025 Intuitive beat Wall Street estimates with revenue of $2.44 billion (+21% y/y) and adjusted EPS of $2.19 (+23% y/y), driven by a 17% rise in worldwide da Vinci procedures (Reuters)
Recurring instruments and accessories revenue grew 18.5% to $1.47 billion in Q2 2025, underpinned by 17% da Vinci, 52% Ion and 88% SP procedure growth, strengthening the high-margin consumables stream (Nasdaq)
In June and July 2025 Intuitive secured Japanese regulatory clearance and EU MDR certification for its next-gen da Vinci 5 system, broadening its addressable markets in two major global regions (SEC)
Tariff headwinds are set to erode Intuitive’s 2025 non-GAAP gross profit margin to 65%–66.5%, down from 69.1% in 2024, reflecting an estimated 1.7% drag on revenue and potentially impeding the company’s ability to win future hospital tenders (Reuters)
Placements of the Ion lung biopsy robot fell 30% year-over-year to 54 units in Q2 2025 versus 74 in Q2 2024, signaling a normalization in demand for the platform and slower adoption than earlier projections (Investors.com)
Management’s 2025 guidance calls for da Vinci procedure growth of 15.5%–17%, below the historical 17%–18% trend, indicating a potential deceleration in procedure volume momentum (Investors.com)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
ISRG Financial Performance
Revenues and expenses
ISRG Earnings Performance
Company profitability
ISRG News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Intuitive Surgical stock?
Intuitive Surgical (ISRG) has a market cap of $157B as of September 26, 2025.
What is the P/E ratio for Intuitive Surgical stock?
The price to earnings (P/E) ratio for Intuitive Surgical (ISRG) stock is 61.11 as of September 26, 2025.
Does Intuitive Surgical stock pay dividends?
No, Intuitive Surgical (ISRG) stock does not pay dividends to its shareholders as of September 26, 2025.
When is the next Intuitive Surgical dividend payment date?
Intuitive Surgical (ISRG) stock does not pay dividends to its shareholders.
What is the beta indicator for Intuitive Surgical?
Intuitive Surgical (ISRG) has a beta rating of 1.65. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.